Trial Profile

A retrospective, observational pilot study of regorafenib or fruquintinib combined with camrelizumab in patients with microsatellite stable (MSS) and/or proficient mismatch repair (pMMR) metastatic colorectal cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Fruquintinib (Primary) ; Regorafenib (Primary)
Indications Colorectal cancer
Focus Therapeutic Use

05 Sep 2025 According to HUTCHMED media release, the company will present data from this study at Chinese Society of Clinical Oncology Annual Meeting 2025, as a oral session taking place on Friday, September 12, 2025 15:00 to 15:12PM in Jinan, China.
26 Aug 2021 New trial record
01 Jul 2021 Results published in the Neoplasma.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com